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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is the third-leading cause of death worldwide.
Identifying COPD-associated DNA methylation marks in African-Americans may contribute to our understanding
of racial disparities in COPD susceptibility. We determined differentially methylated genes and co-methylation
network modules associated with COPD in African-Americans recruited during exacerbations of COPD and smoking
controls from the Pennsylvania Study of Chronic Obstructive Pulmonary Exacerbations (PA-SCOPE) cohort.
Methods: We assessed DNA methylation from whole blood samples in 362 African-American smokers in the
PA-SCOPE cohort using the Illumina Infinium HumanMethylation27 BeadChip Array. Final analysis included
19302 CpG probes annotated to the nearest gene transcript after quality control. We tested methylation
associations with COPD case-control status using mixed linear models. Weighted gene comethylation networks
were constructed using weighted gene coexpression network analysis (WGCNA) and network modules were
analyzed for association with COPD.
Results: There were five differentially methylated CpG probes significantly associated with COPD among
African-Americans at an FDR less than 5 %, and seven additional probes that approached significance at an
FDR less than 10 %. The top ranked gene association was MAML1, which has been shown to affect NOTCH-dependent
angiogenesis in murine lung. Network modeling yielded the “yellow” and “blue” comethylation modules which were
significantly associated with COPD (p-value 4 × 10-10 and 4 × 10-9, respectively). The yellow module was enriched for
gene sets related to inflammatory pathways known to be relevant to COPD. The blue module contained the top
ranked genes in the concurrent differential methylation analysis (FXYD1/LGI4, gene significance p-value 1.2 × 10-26;
MAML1, p-value 2.0 × 10-26; CD72, p-value 2.1 × 10-25; and LPO, p-value 7.2 × 10-25), and was significantly associated with
lung development processes in Gene Ontology gene-set enrichment analysis.
Conclusion: We identified 12 differentially methylated CpG sites associated with COPD that mapped to biologically
plausible genes. Network module comethylation patterns have identified candidate genes that may be contributing to
racial differences in COPD susceptibility and severity. COPD-associated comethylation modules contained genes
previously associated with lung disease and inflammation and recapitulated known COPD-associated genes. The genes
implicated by differential methylation and WGCNA analysis may provide mechanistic targets contributing to COPD
susceptibility, exacerbations, and outcomes among African-Americans.
Trial registration: Trial Registration: NCT00774176, Registry: ClinicalTrials.gov, URL: www.clinicaltrials.gov, Date of
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Background
Chronic obstructive pulmonary disease (COPD) is an
incurable lung disease characterized by progressive airflow
obstruction involving emphysematous destruction of lung
parenchyma and mucus hypersecretion with chronic bron-
chitis. Over 12 million Americans are affected by COPD,
which is the third leading cause of death in the US, [1] and
projected to become the third leading cause of death world-
wide [2]. Recent data suggest that the prevalence of emphy-
sema, chronic bronchitis, and COPD hospitalizations are
increasing among African-Americans (AA), [3–5] and that
AA may develop COPD at a younger age than those who
racially self-identify as white (WH) [5]. In addition, AA
males have one of the highest prevalence rates of smoking
(25.5 %) among racial groups in the United States, [6] lead-
ing to a predictable growing burden of lung disease in this
group. AA individuals present with similar severity of air-
flow obstruction as WH, despite fewer pack-years of smok-
ing [5]. Once they have developed COPD, AA have lower
quality of life scores [7]. Despite these alarming trends,
COPD has been understudied in African-Americans.
Race is an important contributor to genetic [8] and
epigenetic variability, and recent studies have identified
epigenetic association signals that differ between racial
groups [9]. Similarly, the results of differential methylation
association studies of complex traits in single racial-
ancestry cohorts may miss epigenetic risk factors in
another racial-ancestry cohort, and may not be generalizable
to other racial cohorts at all [10, 11]. Recent methylation
studies have shown a subset of methylation signals particular
to AA smokers, [9] but to our knowledge investigations of
epigenetic associations in AA with COPD have not been
previously performed. Understanding the epigenetic associa-
tions of smoking and COPD in AA current and former
smokers may provide insights into features relevant to
COPD-related disparities in AA that may inform treat-
ment within these groups as well as point out disease
pathways applicable to all people with COPD.
DNA methylation patterns are determined at multiple
time points in the life of an individual, [12] including in
utero during imprinting, tissue-specific methylation during
development, and changes in the methylation of genes in
response to major environmental exposures. Differen-
tial methylation impacts gene regulation, which may
lead to clinically relevant changes in disease-related pheno-
types. Modules of genes with correlated comethylation pro-
files may identify groups of genes under similar regulation
that are associated with COPD risk. Prior research has
identified differential methylation signals related to tobacco
smoke exposure that may influence risk for development of
COPD [13–18]. The majority of these studies have focused
on WH subjects as the largest proportion of their co-
horts. Our investigation focused on the identification of
differential methylation sites associated with COPD as
well as COPD-associated comethylation modules in an AA
cohort (the Pennsylvania Study of Chronic Obstructive
Pulmonary Exacerbations, PA-SCOPE), with comparison to
a separate WH cohort (the International COPD Genetics
Network, ICGN). Our hypothesis was that patterns of
DNA methylation in AA would identify differentially
methylated genes or comethylation networks relevant
to COPD in AA that may not be significantly associated
in WH cohorts. A better understanding of the epigenetic
factors associated with the features of COPD in AA
smokers may provide insights into new diagnostic options,
drive the discovery and targeting of therapeutics, and
improve primary prevention strategies in this suscep-
tible population.
Results
After quality control, the PA-SCOPE dataset included
methylation data on 19302 probes measured in 93 AA
subjects with COPD defined by GOLD spirometry criteria
(GOLD I-IV), as well as 269 smoking controls. A quality
control schematic is provided in Fig. 1. Technical replicates
for one male and one female sample plated repeatedly
showed over 99 % intra-sample methylation concordance.
Baseline statistics for PA-SCOPE cases and controls showed
expected differences in metrics used to define COPD
severity including forced expiratory volume in 1 s as
percent predicted (FEV1), forced vital capacity as per-
cent predicted (FVC), and the ratio of FEV1 to FVC
(FEV1/FVC), while pack-year history of smoking (PYH)
was similar. Baseline data for PA-SCOPE and ICGN is
presented in Tables 1 and 2.
Differential DNA Methylation Analysis
We used linear mixed models to identify COPD-associated
CpG sites, using the method of Benjamini and Hochberg to
control type I error. Five differentially methylated CpG sites
were associated with COPD (Table 3) at FDR less than 5 %.
All of these five CpG sites exhibited relative hypomethyla-
tion in association with the presence of COPD. The mean
difference in percent methylation between cases and
controls among the top five associated sites ranged from
5.3 to 9.6 %. The top differentially methylated CpG site
was cg16361890 (unadjusted p-value 8.188 × 10-8, percent
methylation change -7.8 %), which mapped to the MAML1
gene. Gene annotation for the remaining four differentially
methylated CpG sites associated with COPD included
RBFOX2, CD72, GRASP, and SH3TC1.
Seven additional differentially methylated CpG sites were
associated with COPD at FDR of less than 10 %, (Table 3).
These seven additional CpG sites (annotated to FOLR3,
ELOVL3, FAXDC2, FXYD1/LGI4, GABRR1, IFNGR2, and
LPO) also exhibited relative hypomethylation in association
with COPD. The mean difference in methylation between
cases and controls ranged from 7.5 to 11.9 %. These
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differential methylation results are presented in a volcano
plot (Fig. 2) and a Manhattan Plot (Fig. 3).
Comparison to WH Dataset
We next examined the COPD-associated differential methy-
lation sites discovered in the PA-SCOPE AA cohort in the
ICGN WH cohort methylation data [19]. We qualitatively
compared the magnitude of the difference of COPD-
association test-statistic between AA and WH at each
differentially methylated CpG site (PA-SCOPE test-
statistic minus ICGN test-statistic) from the mixed linear
model output (Additional file 1: Table S1 and Figure S1).
We posited that a large difference in test statistic at a
Fig. 1 Subject- and Probe-Level Quality Control Chart. Quality control of the PA-SCOPE methylation dataset included Probe-level controls and
Subject-level quality controls (see Methods for details). Final analysis included 93 COPD cases and 269 smoking controls. SNP-Under-Probe refers
to probes containing a CpG within 5 base pairs upstream or downstream of a known genomic SNP. Repeat-Under-Probe refers to probes that
mapped to genomic repeat regions
Table 1 Baseline statistics among African-Americans in PA-SCOPE
Cases Controls
N= 93 269
Age (years) 61.4 ±7.7 48.9 ± 6.4
FEV1/FVC Ratio 0.434 ± 0.123 0.799 ± 0.053
FEV1 percent predicted 36.8 ± 15.4 89.9 ± 12.5
FVC percent predicted 67.5 ± 22.4 90.7 ± 12.3
Gender (% male) 50 53.8 195 72.5
Pack-Years of Smoking 42.2 ± 22.1 39.2 ± 20.5
Table 2 Baseline statistics among whites in ICGN
Cases Controls
N= 678 427
Age (years) 59.2 ± 7.4 54.9 ± 9.0
FEV1/FVC Ratio 0.412 ± 0.137 0.747 ± 0.052
FEV1 percent predicted 41.3 ± 16.8 99.6 ± 14.4
FVC percent predicted 73.2 ± 20.0 106.3 ± 15.7
Gender (% male) 389 57.4 216 0.506
Pack Years of Smoking 49.7 ± 26.0 29.4 ± 20.7
Data is presented as count with proportion in parentheses or mean with
standard deviation
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Table 3 Differentially Methylated CpG Probes Associated with COPD Among African- Americans in PA-SCOPE
Chromosome CpG Probe Nearest Gene Mean Difference in
Percent Methylation
p-value FDR Adjusted p-value
5 cg16361890 MAML1 -7.8 8.19E-08 0.001
22 cg00615377 RBFOX2 -5.3 1.20E-07 0.001
9 cg12971694 CD72 -9.0 2.05E-06 0.013
12 cg22566906 GRASP -7.8 7.27E-06 0.029
4 cg02635407 SH3TC1 -9.6 7.47E-06 0.029
11 cg25634666 FOLR3 -10.8 3.23E-05 0.080
10 cg18390025 ELOVL3 -8.4 3.40E-05 0.080
5 cg10257049 FAXDC2 -7.5 3.58E-05 0.080
19 cg27461196 FXYD1/LGI4 -11.9 4.27E-05 0.080
6 cg00333528 GABRR1 -8.0 4.43E-05 0.080
21 cg17356733 IFNGR2 -11.9 4.56E-05 0.080
17 cg24489015 LPO -10.8 5.82E-05 0.094
Data are presented in decreasing order of significance. Mean difference in percent methylation represents the mean difference in percent methylation between
cases and controls; p-values were adjusted for multiple comparisons using the method of Benjamini and Hochberg
Fig. 2 Differentially Methylated CpG Probes Associated with COPD. Differential methylation analysis revealed 12 CpG sites in 12 genes significantly
associated with COPD with an FDR-corrected p-value less than 0.10. Difference in mean percent methylation represents the difference in mean methylation
between COPD cases and smoking controls. The y-axis represents the negative log of the association p-value from linear mixed models adjusted for age,
gender, pack years of smoking, assay batch, and cell type. The name of the nearest gene is included with each of the top five CpG results
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given CpG site between the PA-SCOPE and ICGN studies
could indicate a difference in differential methylation be-
tween AA and WH related to COPD case-control status.
This difference metric was found to have a normal distri-
bution (mean = -0.316, sd = 1.515) across the ~19000
probes remaining after data cleaning. Seven of the 12 dif-
ferentially methylated genes identified at FDR less than
10 % in the primary PA-SCOPE analysis were found to
have test-statistic-difference values in the lower 2.5 per-
centile tail of this distribution, supporting the presence of
statistically significant differential methylation at these
sites in the presence of COPD in AA but not in WH.
Weighted gene comethylation network analysis
Weighted Gene Coexpression Network Analysis software
(WGCNA) was used to create a scale-free comethylation
network (see Additional file 1: Figure S2) [20, 21]. The re-
sultant network contained ten modules (see Fig. 4), of
which two were significantly correlated with COPD case-
control status (labeled “blue” and “yellow” modules). The
blue module contained 5009 probes (p-value 4 × 10-9 for
module association with COPD status), and the yellow
module contained 1698 probes (p-value 4 × 10-10 for mod-
ule association with COPD status). The association of the
blue and yellow module eigengenes remained statistically
significant (p-value 1.6 × 10-4 for blue module, 5.5 × 10-5
for yellow module) in a logistic regression model of COPD
affection status after controlling for age, gender, and pack-
years of smoking history.
We investigated the two COPD-associated network
modules for genes previously related to COPD. This
investigation included genes from the differential methyla-
tion analysis results and genes found to be associated with
COPD and lung function measurements in genome-wide
association studies (GWAS) (see Table 4). CpG sites mark-
ing 11 of the 12 top differential methylation sites found in
our differential methylation analysis (GRASP, FXYD1/LGI4,
MAML1, FOLR3, CD72, LPO, GABRR1, SH3TC1, RBFOX2,
IFNGR2, ELOVL3) were part of the blue module. CpG sites
marking the COPD- and lung function-associated genes
NOTCH4, SERPINA1, FAM13A, TNS1, PPT2, CHRNA5,
PPAP2B, CHRNA3, RARB, CHRNA4, ARMC2, CCDC38,
MECOM, ADAMTS19, HHIP, and ZKSCAN3/ZSCAN31
were also all found within the blue module. We limited
both the blue and yellow modules to those genes with a
stringent module membership (kME value) cutoff of 0.85
for further analysis, [21] yielding a gene set of 317 members
and 151 members, respectively.
Fig. 3 Manhattan Plot of Differential Methylation Analysis Results. Differential methylation analysis results presented by chromosomal location
(x-axis). The y-axis represents the negative log of the association p-value from linear mixed models adjusted for age, gender, pack years of smoking,
assay batch, and cell type. The name of the nearest gene is included with each of the top five CpG results
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Gene set enrichment analyses of the limited modules
were performed using GO Biological Processes ontology,
KEGG, and Reactome pathways. The limited blue module
of 317 genes was enriched for developmental gene sets,
with statistically significant enrichment found in GO
pathways such as anatomical structure development
(GO:0048856; adjusted p-value 3.6 × 10-10), branching
morphogenesis of an epithelial tube (GO:0048754; adjusted
p-value1.5 × 10-4), lung morphogenesis (GO:0060425; ad-
justed p-value 0.01), lung lobe morphogenesis (GO:0060425;
adjusted p-value 0.0246), lung development (GO:0030324;
adjusted p-value), and lung lobe development (GO:0060428;
p-value 1.38 × 10-3). The limited yellow module of 151 genes
was enriched for immune/inflammatory gene sets, such as
response to other organism (GO:0051707; adjusted p-value
8.3 × 10-4), immune response (GO:0006955; adjusted p-value
7.3 × 10-3), defense response to bacterium (GO:0071219;
adjusted p-value 4.2 × 10-3), and chemotaxis of natural
killer cells, neutrophils, and eosinophils (GO:0035747,
0030593, 0048245, respectively; adjusted p-values
3.5 × 10-2 to 7.2 × 10-3).
Discussion
Within the PASCOPE AA cohort, we identified 5 differen-
tially methylated CpG sites significantly associated with
COPD using an FDR of 5 %, and 7 additional associations
that approached significance using an FDR of 10 %. We
used WGCNA to identify comethylation modules associ-
ated with COPD that were enriched for genes related to
lung development and immune response and contained
biologically relevant genes associated with COPD and lung
function. Differentially methylated CpG sites associated
with COPD mapped to genes that were biologically plaus-
ible candidates for COPD pathogenesis. Notable functions
among these genes included NOTCH4-dependent lung
angiogenesis, alveolar macrophage response pathways, and
airway defense mechanisms targeting bacteria, as detailed
below. Our results included genes and CpGs implicated in
previous studies of obstructive lung disease and exacer-
bations, including GRASP and IFNGR2 (previous genetic
associations with asthma) as well as FYXD1 (differential
methylation associated with response to systemic steroids
and COPD) [15, 22]. Only 1 of these 12 differentially
Fig. 4 WCGNA Module Trait Relationship Heatmap. Heatmap showing comethylation module correlation with phenotypic trait and associated p-value
for these correlations within PA-SCOPE. Positive or negative correlation magnitude with COPD is presented with p-value for the correlation with COPD
in parenthesis. The yellow and blue modules were both significantly associated with COPD affection status, labeled “COPD”
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methylated CpG sites (cg27461196, mapped to LGI4/
FXYD1) was statistically significantly associated with COPD
at an FDR of 5 % in an independent, larger WH COPD
methylation dataset cleaned and processed in a comparable
way. In addition, in a qualitative comparison of the differ-
ence in differential methylation of CpG sites between AA
and WH, many of our results were statistically significant
for differential hypomethylation only in AA.
The majority of our significantly associated (FDR less
than 10 %) differential methylation CpG sites are located in
genes that are biologically plausible genes for lung disease
that may affect the pulmonary, immune, and vascular
biology of COPD based on previously published data.
Additionally, many of these genes are expressed in either
lung (MAML1, RBFOX2, GRASP, FAXDC2, FXYD1/LGI4,
IFNGR2) or whole blood (IFNGR2) based on GTEx data
showing a median reads per kilobase of transcript per
million reads (RPKM) >10 in these tissues, [23] provid-
ing further support for their potential effects on lung
pathology and disease.
Table 4 COPD-related Genes from WGCNA blue comethylation module








cg22566906 GRASP -0.52 7.06E-27 0.76 8.62E-71
cg27461196 FXYD1/LGI4 -0.52 1.19E-26 0.76 7.10E-70
cg16361890 MAML1 -0.52 1.98E-26 0.83 1.28E-93
cg14700707 NOTCH4 -0.52 2.61E-26 0.72 1.52E-59
cg25634666 FOLR3 -0.51 1.82E-25 0.78 3.50E-76
cg12971694 CD72 -0.51 2.11E-25 0.84 7.77E-99
cg24489015 LPO -0.50 7.21E-25 0.79 2.57E-78
cg00333528 GABRR1 -0.50 7.29E-25 0.83 5.25E-94
cg02635407 SH3TC1 -0.50 7.93E-25 0.85 1.02E-102
cg00615377 RBFOX2 -0.49 1.25E-23 0.87 1.20E-111
cg11394785 MAML1 -0.48 5.73E-23 0.78 2.39E-75
cg17356733 IFNGR2 -0.48 1.79E-22 0.83 6.93E-95
cg18390025 ELOVL3 -0.48 1.83E-22 0.84 4.19E-97
cg02181506 SERPINA1 -0.45 8.76E-20 0.74 7.93E-65
cg04536922 FAM13A -0.45 1.62E-19 0.87 1.49E-114
cg00431050 ELOVL3 -0.39 1.57E-14 0.69 3.83E-52
cg18328334 TNS1 -0.37 2.87E-13 0.54 4.75E-29
cg04845063 FAM13A -0.36 1.38E-12 0.80 1.97E-84
cg12585943 PPT2 -0.29 2.72E-08 0.59 5.39E-35
cg22563815 CHRNA5 -0.29 2.84E-08 0.52 1.72E-26
cg16505550 PPAP2B -0.23 7.46E-06 0.38 5.96E-14
cg04603031 CHRNA3 -0.22 2.28E-05 0.66 7.85E-47
cg27486427 RARB -0.22 3.08E-05 0.90 2.67E-130
cg00318573 CHRNA4 -0.19 1.77E-04 0.58 9.87E-35
cg03874127 ARMC2 -0.18 6.61E-04 0.57 2.36E-33
cg25229172 CCDC38 -0.17 8.09E-04 0.43 8.49E-18
cg19848683 MECOM -0.14 6.09E-03 0.75 5.35E-67
cg13701109 ADAMTS19 -0.14 7.38E-03 0.71 1.57E-57
cg06334284 PPAP2B -0.13 1.11E-02 0.82 7.50E-92
cg14228238 MECOM -0.12 2.55E-02 0.60 1.41E-37
cg14580567 HHIP -0.04 4.24E-01 0.61 3.32E-39
cg21750589 ZKSCAN3/ZSCAN31 -0.04 4.95E-01 0.26 4.78E-07
Summary of “gene significance to phenotype” values and “blue module membership” values of genes previously associated with COPD and lung function through
GWAS, as well as differentially methylated sites discovered in the differential methylation analysis
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Two of the disease-associated genes were associated with
COPD in prior studies. Folate Receptor Gamma (FOLR3)
was found to be 15- to 20-fold upregulated during stable
COPD and acute exacerbations of COPD in previous
studies, [24] although the mechanistic and functional
implications of this upregulation are unclear. Differential
methylation of Phospholemman (FXYD1) was shown to
be associated with COPD in the ICGN cohort by Qiu et
al, [15] and this gene was also previously found to be dif-
ferentially methylated in response to systemic steroid use
in COPD [22]. Both of these genes are notably related to
acute exacerbations of COPD as well as a preferred treat-
ment modality (systemic steroids) for acute exacerbations.
The PASCOPE study recruited subjects who were hospi-
talized for acute exacerbations of COPD, and blood draws
for DNA methylation analysis were performed during the
inpatient hospitalization. Because of the timing of our
sampling, the methylation pattern of these genes may be
related to a confounder such as acute exacerbations of
COPD, systemic steroid use, recent smoking, or to a sub-
set of subjects in our dataset with a phenotype of frequent
exacerbations, although this could not be directly assessed
based on our data.
Five CpG sites were annotated to genes related to
pulmonary and airway physiology. Lactoperoxidase (LPO)
is secreted by submucosal glands in human bronchi and
plays a role in human airway host defense against bacteria
[25]. Gamma-aminobutyric acid Receptor1 (GABRR1) has
been shown to affect alveolar fluid homeostasis in alveolar
epithelial type II cells [26]. Upregulated gene expression of
Very Long Chain Fatty Acid Elongase3 (ELOVL3) has
been proposed to contribute to dysregulated lipid droplet
formation in pulmonary surfactant in response to par-
ticulate exposure [27]. Rare missense mutations of GRP1-
Associated Scaffold Protein (GRASP) were previously
associated with asthma in a Latino cohort [28]. The func-
tion of SH3 Domain and Tetratricopeptide Repeats 1
(SH3TC1) has not been adequately described in the lung;
however, it is implicated in networks related to bronchial
airway epithelial cells and cigarette smoking [29].
An additional three CpG sites were annotated to genes
related to immune response and steroid synthesis.
Cluster of Differentiation 72 (CD72) is a CD5 co-ligand
involved in hypersensitivity reactions and sarcoidosis, highly
expressed in pulmonary alveolar macrophages [30]. Fatty
Acid Hydroxylase Domain Containing2 (FAXDC2) is impli-
cated in “steroid biosynthesis” through KEGG pathways
[31]. Interferon Gamma Receptor 2 (IFNGR2) plays a role
in activation of macrophages and regulation of Th1 re-
sponse to intracellular pathogens, with genetic variants
previously associated with atopic asthma [32] and pul-
monary tuberculosis.
The final two CpG sites were related to cardiovascular
processes. Mastermind-Like1 protein (MAML1) effects
angiogenesis during organ development through NOTCH-
dependent signaling in murine lung [33]. RNA-binding
Protein Fox-1 Homolog 2 (RBFOX2) is a splicing regulator
implicated in differentiation of myofibroblasts to skeletal
muscle, and diminished expression previously associated
with pressure-overload-mediated progression of dilated
cardiomyopathy/heart failure; [34] potential impact on
airway smooth muscle has not been described.
We present data showing that many of our top COPD-
associated CpG sites are located in the lower tail of a histo-
gram of the difference in test-statistic between CpG sites in
the African-American PA-SCOPE dataset and the white
ICGN dataset (see Additional file 1: Figure S1) using simi-
lar model parameters and adjustment for covariates. This
finding may represent qualitative evidence that these sites
are more differentially methylated in African-Americans
compared to whites, although this conclusion must be seen
as hypothesis-generating only without a separate properly
controlled and matched study design that would be free of
confounding by technical artifacts related to batch.
Boxplots of the unadjusted absolute methylation at these
sites in both PA-SCOPE and ICGN (see Additional file 1:
Figure S3) reveal that the methylation difference between
cases and controls is consistent with hypomethylation in
COPD cases among both AA and WH, however only
among the AA subjects is the difference statistically sig-
nificant. The relative differential hypomethylation of
these CpGs among AA subjects compared to WH sub-
jects could be explained by several scenarios. The most
mechanistically attractive possibility is that these CpG
sites represent differential methylation events in response
to gene-environment interactions experienced preferentially
by African-Americans. The second mechanistic possibility
is that these CpG sites represent blood methylation quanti-
tative trait loci (mQTL) that are influenced by the genetic
architecture specific to the population substructure [35] of
African-Americans. In both of the preceding scenarios, the
differential methylation could in turn impact damage and
airflow obstruction through changes in gene expression
and protein production, which could present unique targets
for intervention. Finally, the differential methylation may
simply be a marker of a confounder between methylation
state and COPD, tagging a prior or recent exposure
(such as smoking) that directly contributed to both
disease and CpG methylation through distinct mecha-
nisms. Blood draws in the PA-SCOPE COPD case sub-
jects occurred during inpatient hospitalizations for
acute COPD exacerbations, while blood draws for non-
COPD control subjects occurred during study-related
office visits; this could lead to potential confounders of
our COPD associations including COPD exacerbation,
inpatient medication use including corticosteroids, ex-
acerbation triggers such as viral or bacterial infections,
or other unmeasured variables.
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WGCNA identifies modules of comethylated genes
starting from the level of thousands of CpG probes
and correlates these modules to phenotypic variables.
The network creation and module-building processes
of WGCNA are informed purely by gene methylation
levels, without consideration of case-control status for
COPD. Individual genes within the module can then
be related to the module eigengenes by measures of
module membership and gene significance to the
module. This technique identifies driver genes for the
module that may help identify biologically meaningful
pathways. In our dataset the yellow and blue modules
showed significant association with COPD. Yellow module
measures of gene significance were predominantly positive
(indicating positive correlation of module comethylation
in association with COPD) while the blue module con-
tained primarily negative measures of gene significance
(indicating negative correlation of module comethylation
in association with COPD).
Further investigation of the blue module showed a
network with biological significance for obstructive
lung disease. The module was statistically enriched for
pathways related to lung development, and also contained
multiple genes previously associated with COPD and lung
function. SERPINA1 is the gene responsible for alpha-1-
antitrypsin deficiency, [36] a known genetic cause of COPD,
and this gene was found to be highly significant in the blue
module. The blue module also contained multiple genes
previously associated with COPD or lung function mea-
surements through GWAS. WGCNA modules are com-
posed of genes with similar methylation states, which could
give insight into processes of coregulation between these
genes. While the SEPRINA1 mutations known to cause
alpha-1 antitrypsin deficiency are uncommon in AA, one
could hypothesize from this data that coregulation of the
SERPINA1 gene through DNA methylation (and other
genes related to lung development in the blue module)
could contribute to COPD susceptibility in a disease mod-
ule framework. However, this hypothesis would require
further study with larger datasets including additional mo-
dalities such as gene expression. Many of the CpG sites
found in the differential methylation analysis were also
found in the blue module with high measures of module
membership (indicating importance of the gene to the
module) and high measures of gene significance to COPD.
The recapitulation of these CpG sites in the same module
as previously known COPD- and lung-function-related
genes adds validation to our differential methylation results.
The yellow module, by comparison, contained genes
enriched for immune response pathways. Chronic inflam-
mation in response to airway damage from cigarette smok-
ing as well as external pathogens are recognized as integral
parts of the pathogenesis of COPD and exacerbations
[37–39]. Enrichment for the chemotaxis of effector cells
that are known to play a role in COPD pathogenesis (neu-
trophils, [40] eosinophils, [41, 42] and natural killer cells
[43]) were found using yellow module genes with high
module membership values. The PA-SCOPE population
was ascertained using subjects with disease exacerbations,
so this population may have been enriched for signals as-
sociated with acute inflammation and immune response
[44, 45].
The PA-SCOPE dataset was a retrospective case-control
study and so no direct causation can be inferred from re-
sults, only associations of CpG sites with disease. DNA
methylation in response to smoking is a dynamic process,
and effects may be time-dependent; longitudinal profiling
of methylomes and phenotypes is needed [16, 46]. Our data
did not contain information on the duration of COPD in
our subjects, so we could not assess whether this might im-
pact on our results. COPD is often underdiagnosed or diag-
nosed at more severe stages of disease, [47, 48] however, so
duration of COPD could potentially be unreliable in statis-
tical models comparing COPD cases and controls. While
our data did contain information related to spirometric
severity of COPD, we were underpowered to detect signifi-
cant differential DNA methylation site associations with
COPD severity due to sample size. The methylation dataset
for PA-SCOPE did not contain data related to current
smoking or time since quitting smoking, and we could not
assess the effects that these important variables might have
on our differential methylation results in association with
COPD. Multiple studies have shown that smoking history
affects DNA methylation, and a recent study showed that a
subset of these DNA methylation effects are dynamic in a
time-dependent fashion after smoking cessation, [46] how-
ever our data did not allow us to control for smoking cessa-
tion or time since quitting. Data on chronic or inpatient
medication use was also not available, which limits our abil-
ity to control for these potential confounders. Longitudinal
data was not available in PA-SCOPE, so further conclusions
integrating clinical stability, clinical progression, or other
lung function trajectories [49] associated with CpG sites
cannot be made using these data. Without paired gene ex-
pression data, it is unclear what effect these differentially
methylated sites have on expression of the associated gene
products. While both PA-SCOPE and ICGN were studies
of COPD subjects and smoking controls, differences in as-
certainment of the datasets may influence the conclusions.
Notably, the PA-SCOPE dataset compared AA subjects
recruited during inpatient COPD exacerbations with
controls without known lung disease or recent respira-
tory illness. The ICGN dataset compared WH subjects
with COPD (with no selection criteria related to COPD
exacerbations) with control family members. Because of
this difference, our differential methylation site associations
with COPD could be confounded by potential methylation
effects related to COPD exacerbations. Similarly, the
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comparison of test-statistic differences between ICGN
and PA-SCOPE could be influenced by factors other
than racial differences in differential methylation related
to COPD. Race was determined by self-report and no gen-
etic testing of ancestry or admixture was performed,
thus individuals of mixed genetic ancestry who self-
identified as African-American may be included in our
analyses and these data may be a source of residual
confounding. Batch effects between the PA-SCOPE and
ICGN assays, differences in ascertainment and study
design related to the timing of COPD exacerbations,
and baseline differences in the two populations other
than racial make-up could also account for the differ-
ences in statistical association among these populations,
so we present these data points as qualitative and
hypothesis-generating for further investigations.
The Illumina Infinium HumanMethylation27 BeadChip
Array interrogates only a subset of CpG sites in the human
epigenome, and additional unmeasured sites may be differ-
entially methylated in association with COPD. Specifically,
the HumanMethylation27 BeadChip’s design focused on
CpG sites within transcription start sites of over 14,000
genes and additional coverage of around 200 cancer-related
genes [50]. Additional information on genes not repre-
sented on the array as well as additional CpGs in promoter
regions, enhancer regions, or the gene body might yield
additional associations with COPD and would be an area
for further investigations. This study focused on DNA
methylation; however other epigenetic changes such as his-
tone acetylation and chromatin modification could impact
gene regulation and have relevant associations with COPD;
these other modalities were not assayed in our study.
We assayed whole blood for DNA methylation signals
associated with COPD, but not lung tissue samples. Prior
studies have shown associations between smoking and
DNA methylation in whole blood [9, 17, 46]. DNA methy-
lation of lung tissue could potentially capture information
related to additional airborne environmental exposures
relevant to COPD, which might not be present in DNA
methylation from peripheral blood alone. While lung
tissue DNA methylation could provide additional insight
into disease mechanisms, the additional risks and costs of
obtaining lung tissue are not trivial, and human lung tissue
itself is a heterogeneous mixture of cell types [51]. However,
some whole blood CpG sites may recapitulate DNA methy-
lation signals related to lung exposures [52] or lung disease,
[53] and we examined our data in this context. While total
pack-years of smoking was a covariate within our models,
additional unmeasured variables related to environmental
exposure may impact the findings. One could hypothesize
that disease mechanisms related to organ development, sys-
temic inflammation, immune response, and protease activ-
ity might be best represented in whole blood compared to
lung tissue, and our results may reflect this. Additional
studies including contemporaneous collections of whole
blood and lung tissue would be needed to gain additional
insight into these relationships. We present statistically
significant differentially methylated CpG associations with
COPD with strict multiple testing corrections, however
these results need replication in separate datasets. Future
studies including large populations of both AA and WH
would be needed to further validate both the differential
methylation results as well as the race-specificity of our
results. The recapitulation of many of our differentially
methylated genes in network modules strongly associated
with COPD provides some biological validation of the im-
portance of these sites to COPD using a different analytic
approach.
Conclusion
In conclusion, we performed differential methylation
analysis in African-American subjects and identified 12
CpG sites statistically significantly associated with COPD
at an FDR less than 10 %, of which seven are not statisti-
cally significant in a WH cohort study of COPD. We also
performed weighted gene comethylation network analysis
and identified two comethylation modules associated with
COPD in AA, one of which included multiple genes re-
lated to obstructive lung disease and COPD. This module
was enriched for lung-specific gene sets and our results
add to insights into molecular mechanisms that may con-
tribute to lung disease disparities in African-Americans.
Molecular mechanisms for COPD-related outcomes in
AA smokers have not been adequately investigated. While
further research is needed to understand the biological
consequences of differential methylation of the genes we
identified, they represent promising genes for mechanistic
investigations of COPD in AA and for the consideration
of epigenetic contributions to racial disparity in COPD
susceptibility and severity.
Methods
Subjects and data collection
Researchers at Temple University and the Pennsylvania
Department of Public Health designed the Pennsylvania
Study of Chronic Obstructive Pulmonary Exacerbations
(PA-SCOPE, ClinicalTrials.gov Identifier: NCT00774176)
as a collaborative observational study to identify demo-
graphic and genetic factors that contributed to COPD exac-
erbations among AA smokers with COPD in urban and
rural Pennsylvania. Subject recruitment and data gathering
occurred between June 2004 and May 2008. Additional
details of the PA-SCOPE study design can be found in
Additional file 1. Subjects in the PA-SCOPE methylation
dataset were selected from the PA-SCOPE AA study
population. PA-SCOPE data types for each of 371 AA sub-
jects in the methylation cohort consisted of questionnaire
data, spirometry and pulmonary function tests, and DNA
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extracted from whole blood samples. All subjects in the
methylation dataset analyzed were male and female AA
smokers (>20 pack-year history) ages 40-80 years of age.
Exclusion criteria for the PA-SCOPE study included <20
pack-years of smoking history, life expectancy <6 months
due to any cause, alpha-1 antitrypsin deficiency, or a
previous diagnosis of pulmonary fibrosis, bronchiectasis,
mediastinal mass, or a pulmonary mass. Subjects with
asthma by prior history, lack of a significant smoking his-
tory, and or evidence of significant spirometric reversibility
with bronchodilator (FEV1 increase >15 %) were excluded.
COPD cases were subject to additional inclusion criteria in-
cluding inpatient hospitalization for an acute exacerbation
of COPD at the time of study entry and a spirometric diag-
nosis of COPD without significant bronchodilator response.
Acute exacerbations of COPD were defined using criteria
of worsening dyspnea, increase sputum volume and
sputum purulence [54]. Control subjects were assessed
at a routine study-related outpatient visit and met in-
clusion criteria for smoking history and age, but were
excluded if they met spirometric criteria for COPD or
had a history of a COPD diagnosis. Exclusion criteria
in both cases and controls did not include assessment
of other smoking-related comorbidities such as coronary
artery disease, cerebrovascular disease, non-pulmonary
and non-mediastinal malignancies, and diabetes. Race was
determined by self-report. Blood draws for COPD cases
were performed during inpatient hospitalizations for
COPD exacerbations, while blood draws for controls were
acquired during the routine study-related office visit.
Spirometry of subjects with COPD was performed within
4 to 6 weeks after their inpatient hospitalizations. Partici-
pants provided written consent to participate in this study,
and the study was approved by the institutional review
boards at all participating institutions (Partners IRB:
2005P000453/BWH).
We assessed DNA samples from 371 COPD cases
(defined by FEV1/FVC ≤ 0.7 and FEV1 ≤ 80 % pre-
dicted) and smoking controls for genome wide differ-
ential methylation using the Illumina (San Diego, CA)
Infinium HumanMethylation27 BeadChip (Illumina27K).
The Illumina27K array assays 27,758 CpG dinucleotides
[50] for quantitative measurements of DNA methylation,
covering over 14,000 genes. We included only DNA sam-
ples that had undergone ≤ 2 freeze-thaw cycles prior to
performing the Illumina27K microarray assay. We per-
formed the assay using the manufacturer’s suggested
protocol, including standard controls for bisulfite con-
version, amplification, hybridization, and extension. We
report the percent methylation values ranging from 0
to 100 % (corresponding to beta value of 0 to 1), calcu-
lated as the ratio of the fluorescent intensity of the
methylated bead type (meth) to the combined locus in-
tensity of methylated and unmethylated bead types
(meth + unmeth) plus an offset (beta = meth/(meth +
unmeth + 100)). The log2-ratio of the methylated to
unmethylated intensities (M-value) was used for associ-
ation testing [55]. The absolute difference in percent
methylation between cases and controls was used to
quantify the effect size.
Quality control
The R programming language [56] and the BioConductor
[57] suite of software (packages including methylumi, [58]
GenomicRanges, [59] and wateRmelon [60]) were used for
data annotation, probe quality control and pruning, and
subject-level quality control. The Illumina27K probes were
annotated to their nearest gene using hg19 coordinates. To
eliminate false associations due to SNPs underlying probe
regions, [61] probes containing a CpG overlying a SNP or
within 5 base pairs upstream or downstream of a known
genomic SNP were eliminated. Probes underlying genomic
repeat regions have also been cited as a source of error
using Illumina microarrays, [62] and were eliminated.
Probes interrogating the sex chromosomes were also elimi-
nated. Subject level quality control eliminated one sample
having 1 % of sites with a detection p-value greater than
0.05. CpG sites with a beadcount of less than 3 in greater
than 5 % of samples, and sites having greater than 1 % of
samples with a detection p-value greater than 0.05 were
also removed; 8 subjects’ demographic data were incom-
plete and were removed for the final analysis. Technical
replicates for one male and one female were included to
assess for within-subject correlation across arrays.
Cell type deconvolution
Differential methylation signals arising primarily from
cell type composition of whole blood can bias methylation
analysis. Both smoking and COPD are associated with in-
flammation, and differences in methylation signals between
cases and controls based purely on immune cell type pro-
portion in whole blood could confound association analysis
results. To control for this bias, we performed cell type
deconvolution using the method and software provided by
Houseman et al, [63] which uses the principal components
of the methylation signatures of whole blood cellular
components projected onto a reference sample to create
regression covariates to facilitate adjustment for cell type
heterogeneity between samples.
Differential DNA methylation analysis
Differential methylation analysis was performed on 362
samples after quality control using the limma package
[64]. For the COPD analysis, associations between differ-
entially methylated probes and COPD case-control status
were modeled in a logistic mixed model controlling for age,
gender, pack-years of smoking, batch number, and cell
type deconvolution (principal component-based covariates
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accounting for natural killer cells, CD8+ T-cells, CD4+
T-cells, B-cells, and monocytes). Family-wise type I
error was controlled using the method of Benjamini-
Hochberg to achieve a genome-wide false discovery rate
(FDR) threshold of significance of less than 5 %. Addition-
ally, we examined the results that approached statistical sig-
nificance at less than FDR 10 % level for assessment of
additional biologically-plausible targets. The absolute differ-
ence in the mean percent methylation value was used to
quantify the magnitude and direction of effect for differen-
tially methylated CpG sites; positive values of delta beta
correspond to relative hypermethylation among the cases.
Comparison to WH dataset
An analysis of differential DNA methylation sites associated
with COPD was performed previously by our group using
WH subjects in the ICGN. This dataset has been previously
described, [15] and additional information of the study
design and their baseline characteristics (Additional file 1:
Table S2) is provided in Additional file 1. Whole blood sam-
ples were assayed for DNA methylation on the Illumina27k
array. This dataset included 692 COPD WH cases defined
by FEV1/FVC ≤ 0.7 and FEV1 ≤ 80 % predicted, as well as
437 WH controls, with race and ethnicity determined by
self-report. Blood draws for cases and controls occurred
during routine study office visits. We passed these data
through annotation, quality control, probe control, cell type
deconvolution, and differential DNA methylation analysis
steps that were identical to those used for the PA-SCOPE
dataset. We hypothesized that statistical associations for
differential methylation of genes between AA and WH may
reflect biological differences in disease mechanisms or
disease-relevant exposures. We used this ICGN WH dataset
to compare differential methylation values to those found in
the PA-SCOPE AA cohort. We compared the differential
methylation characteristics of COPD-associated CpG sites
between AAs and WHs qualitatively in order to identify sites
with significant differential methylation in AA without
corresponding differential methylation in WH. In order to
identify those sites at which the difference in differential
methylation was qualitatively greatest between AAs and
WHs, we calculated the difference in test statistic (retaining
direction of effect) for each CpG site between the PA-
SCOPE AA analysis and the ICGNWH analysis.
Weighted gene comethylation network analysis
WGCNA is a network analysis tool that uses hierarch-
ical clustering of correlated methylation states (trans-
formed using the power adjacency function) between
CpG probes to construct weighted comethylation modules
[20]. The eigengene of each module mathematically sum-
marizes the comethylation information of all CpGs within
each module for modeling purposes, and these eigengenes
are subsequently modeled against phenotypic outcomes to
show association between phenotypes and comethylation
modules. While differential methylation analysis examines
one CpG probe at a time, WGCNA incorporates informa-
tion from all probes in a module to evaluate the module’s
association with a trait. Classification of CpG sites and
genes within the same COPD-associated module supports
coregulation of these genes through DNA methylation.
This approach complements the individual CpG site
methylation findings by implicating additional genes that
may not achieve statistical significance through differential
methylation analysis, but may still play a role in phenotypic
association through their comethylation within the module.
Weighted gene comethylation networks were constructed
using the quality controlled PA-SCOPE dataset as input to
the WGCNA R-package by Langfelder and Horvath, [20]
and network modules were analyzed for association with
COPD in a signed correlation network. Scale-free proper-
ties were achieved with a soft thresholding value of 12,
resulting in ten modules. Analysis of the eigengenes of sig-
nificantly COPD-associated modules (measured as the cor-
relation of the gene’s methylation profile with the module
eigenvector) was performed to evaluate driver genes for the
module (genes whose methylation is most highly correlated
to the eigengene methylation). Gene significance is quanti-
fied statistically by the Student’s t-test statistic for differen-
tial methylation between COPD cases and controls, and
larger values of gene significance indicate more contribu-
tion of the gene’s comethylation pattern to the module’s as-
sociation with COPD. Results were inspected for genes in
the differential methylation top results, as well as for known
obstructive lung disease associations from GWAS studies
of lung function [65–67] and COPD [68–73]. For each sig-
nificantly associated eigengene, logistic regression models
of COPD case-control status were constructed using the
module eigengenes and clinical covariates of age, gender,
and pack-years of smoking history to evaluate the ro-
bustness of the eigengene association to COPD. COPD-
associated WGCNA modules were limited to genes with a
stringent module membership (kME value) cutoff of >0.85,
as per previously published methods [21]. Gene set enrich-
ment analysis on these limited modules was performed
using ConsensusPathDB [74] to compare the COPD-
associated module genes to evaluate for enrichment in
the Gene Ontology (GO) Biological Processes ontology,
Kyoto Encyclopedia of Genes and Genomes (KEGG),
and Reactome pathways using hypergeometric testing
controlled for multiple testing using the false discovery
rate method applied to the number of included genes.
Additional file
Additional file 1: Supplementary data and methods are provided in
Additional file 1. This file includes additional methodological details related
to study design, Tables S1 and S2, and Figures S1-S3. (DOCX 3650 kb)
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